Visara
Company
Visara develops one asset, in phase 1 (HT006.2.2 in neurotrophic keratitis). Mostly protein or enzyme acting on NTRK1.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 2
- Signals
Pipeline
1NGF eye drops promote corneal nerve survival and repair.
Phase 1, Protein or enzyme, NTRK1, neurotrophic keratitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals2